立体定向体部放疗联合醋酸阿比特龙治疗寡转移去势抵抗性前列腺癌患者的随机II期试验(ARTO)
ARTO是一项多中心II期随机临床试验,评估在醋酸阿比特龙联合泼尼松(AAP)基础上加用立体定向体部放疗(SBRT)对寡转移去势抵抗性前列腺癌(CRPC)的获益。共入组157例患者,随机1:1接受AAP单药(对照组)或AAP联合SBRT照射全部病灶(试验组)。主要终点为治疗开始后6个月时生化反应率(PSA较基线下降≥50%),试验组为92%,对照组为68.3%,OR为5.34(95%CI 2.05-13.88;P=.001),支持试验组。
要点
- 主要终点生化反应率:试验组92% vs 对照组68.3%,OR 5.34(95%CI 2.05-13.88;P=.001)。
- 完全生化反应率:试验组56% vs 对照组23.2%,OR 4.22(95%CI 2.12-8.38;P<.001)。
- 无进展生存期:试验组较对照组显著改善,HR 0.35(95%CI 0.21-0.57;P<.001)。
核心结论
- 试验达到生化控制和无进展生存期的主要终点,提示在转移性去势抵抗性前列腺癌患者中,一线AAP治疗基础上加用SBRT可能带来临床获益。
研究设计与样本
- ARTO(ClinicalTrials.gov标识符NCT03449719)为多中心II期随机临床试验,纳入寡转移性去势抵抗性前列腺癌患者,定义为非内脏转移病灶≤3个。
- 患者按1:1随机分配接受AAP单药(对照组)或AAP联合SBRT照射全部病灶(试验组)。
- 主要终点为治疗开始后6个月时测量的生化反应率,定义为前列腺特异性抗原(PSA)较基线下降≥50%。
- 完全生化反应(定义为治疗6个月时PSA<0.2 ng/mL)和无进展生存期(PFS)为次要终点。
- 2019年1月至2022年9月期间共入组157例患者。
主要发现
- 生化反应率:试验组92% vs 对照组68.3%,OR 5.34(95%CI 2.05-13.88;P=.001),支持试验组。
- 完全生化反应率:试验组56% vs 对照组23.2%,OR 4.22(95%CI 2.12-8.38;P<.001)。
- SBRT显著改善无进展生存期,试验组较对照组疾病进展的风险比为0.35(95%CI 0.21-0.57;P<.001)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: ARTO (ClinicalTrials.gov identifier: NCT03449719) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS: All patients were affected by oligometastatic CRPC as defined as three or less nonvisceral metastatic lesions. Patients were randomly assigned 1:1 to receive either AAP alone (control arm) or AAP with concomitant SBRT to all the sites of disease (experimental arm). Primary end point was the rate of biochemical response (BR), defined as a prostate-specific antigen (PSA) decrease ≥50% from baseline measured at 6 months from treatment start. Complete BR (CBR), defined as PSA < 0.2 ng/mL at 6 months from treatment, and progression-free survival (PFS) were secondary end points. RESULTS: One hundred and fifty-seven patients were enrolled between January 2019 and September 2022. BR was detected in 79.6% of patients (92% v 68.3% in the experimental v control arm, respectively), with an odds ratio (OR) of 5.34 (95% CI, 2.05 to 13.88; P = .001) in favor of the experimental arm. CBR was detected in 38.8% of patients (56% v 23.2% in the experimental v control arm, respectively), with an OR of 4.22 (95% CI, 2.12 to 8.38; P < .001). SBRT yielded a significant PFS improvement, with a hazard ratio for progression of 0.35 (95% CI, 0.21 to 0.57; P < .001) in the experimental versus control arm. CONCLUSION: The trial reached its primary end point of biochemical control and PFS, suggesting a clinical advantage for SBRT in addition to first-line AAP treatment in patients with metastatic castration-resistant prostate cancer.
引用
- Francolini G, Allegra AG, Detti B, et al. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol. 2023. PMID: 37733977. doi:10.1200/JCO.23.00985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。